Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zai Lab Ltd ( (HK:9688) ) has shared an update.
Zai Lab Limited has granted share options and restricted share units under its 2024 Equity Incentive Plan, issuing 136,819 American depositary shares in options to a single employee and 75,288 ADS-equivalent restricted share units to four employees. The awards, which carry a 10-year option term and four-year vesting schedule without performance targets or clawback provisions, are designed to align employee incentives with long-term shareholder interests and maintain market-competitive compensation.
The stock options are priced at US$20.32 per ADS, slightly above the ADS closing price of US$19.59 on the grant date, while the restricted share units are granted at no purchase price. By expanding equity-based compensation, Zai Lab aims to strengthen employee retention and reinforce its talent strategy, which may support execution of its growth plans and enhance alignment between management and investors as the company navigates the global biopharmaceutical market.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company listed in Hong Kong and the U.S., focused on developing and commercializing innovative medicines. The company operates through a global equity incentive framework to attract and retain specialized talent in the competitive healthcare and life sciences sector.
Average Trading Volume: 11,022,162
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.08B
For a thorough assessment of 9688 stock, go to TipRanks’ Stock Analysis page.